Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2023-05-25 Transaction in Own Shar…
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
首次回购股份暨回购进展情况公告
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the company's share repurchase plan and the progress of the initial repurchase. It details the repurchase purpose, method, price, quantity, funding source, and implementation period, as well as the progress made up to a specific date. The content focuses on the company's buyback of its own shares, including specific numbers and financial details related to the repurchase. There is no indication that this is a full financial report, earnings release, or regulatory filing unrelated to share repurchase. The document length is relatively short (1529 characters), but it contains substantive information about the share repurchase itself, not just an announcement of a report. Therefore, it fits best under the category of Transaction in Own Shares (POS).
2023-05-25 Chinese
2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2022 Annual General Meeting (AGM) resolution announcement for Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results on various reports and proposals related to the 2022 fiscal year. The document includes resolutions passed at the AGM, such as approval of the 2022 board work report, supervisory board report, independent director report, annual report, financial statements, budget report, equity distribution plan, audit reports, and governance changes. It also includes legal opinions confirming the validity of the meeting and voting. The document is not the full annual report or financial statements themselves but an official announcement of the AGM resolutions and voting outcomes. This fits the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)" rather than the full Annual Report (10-K) or other categories. The document length is about 5237 characters, consistent with a detailed announcement but not a full report. Therefore, the correct classification is DVA with high confidence.
2023-05-24 Chinese
上海天璇律师事务所关于四川梓橦宫药业股份有限公司2022年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2022 Annual General Meeting (AGM) of Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the legality and validity of the AGM's convening, attendance, voting procedures, and results. The document includes specific voting results on various proposals discussed at the AGM. It is not the AGM presentation materials themselves but a legal opinion on the AGM process and outcomes. This type of document is best classified under 'Declaration of Voting Results & Voting Rights Announcements (DVA)' because it officially reports the voting results and validates the AGM procedures. The document length (5758 characters) and content confirm it is a detailed legal opinion on the AGM voting results rather than a brief announcement or a full annual report.
2023-05-24 Chinese
投资者关系活动记录表
Call Transcript Classification · 95% confidence The document is an investor relations activity record specifically for an annual report earnings explanation meeting held on May 19, 2023, discussing the 2022 annual report results. It includes detailed Q&A about company performance, strategy, product development, and financial outlook. The document is about the earnings explanation meeting rather than the earnings release itself or the full annual report. The content matches the description of a Call Transcript (CT) as it is a full text transcript of a company conference call or earnings call with Q&A. The document length (5490 characters) supports it being a transcript rather than a brief announcement or a report publication announcement. Therefore, the best classification is Call Transcript (CT).
2023-05-21 Chinese
2022年年度报告业绩说明会预告公告
AGM Information Classification · 95% confidence The document is a short announcement (1006 characters) about a scheduled performance explanation meeting related to the company's 2022 Annual Report. It references the 2022 Annual Report but does not contain the report itself or detailed financial data. The document invites investors to participate in a web-based meeting to discuss the annual report results. This fits the definition of an AGM Information or an Annual Report presentation notice. However, since it is specifically about an 'Annual Report Performance Explanation Meeting' and not the report itself, and given the short length and nature of the announcement, it is best classified as AGM Information (AGM-R).
2023-05-16 Chinese
关于全资子公司完成工商变更登记并换发营业执照的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the completion of a business registration change and issuance of a new business license for a wholly-owned subsidiary. It references a previous announcement about capital increase but does not contain financial statements or detailed financial data. The document length is only 588 characters, indicating it is a brief regulatory announcement rather than a full report. It does not fit categories like Annual Report, Interim Report, or Capital/Financing Update since it mainly informs about a registration change and license issuance. Therefore, it best fits the category of Regulatory Filings (RNS), which is a fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-05-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.